Cardosyl

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardosyl

Quick Facts

Property Description
Active ingredient Perindopril (as the erbumine salt)
Form Tablet (oral administration)
Pharmacological class Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor)
General purpose Antihypertensive agent
Origin Synthetic prodrug

What Type of Medicine is Cardosyl?

Cardosyl is a prescription-only pharmaceutical preparation formally classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, which is clinically recognized for its systemic action as an antihypertensive agent. This classification signifies the drug's specialized function in supporting blood vessel tension and fluid balance. The active compound is Perindopril, which is a synthetic molecule often supplied as the stable salt form, Perindopril erbumine.

Perindopril is defined as a prodrug, meaning it is administered in an inactive form that must be metabolized by the liver to generate its biologically active metabolite, perindoprilat. This requirement for internal conversion is a defining feature of Perindopril compared to non-prodrug ACE inhibitors, positioning it for long-term management in adult patients requiring sustained cardiovascular support.

Composition, Form, and General Purpose

The medication is offered as a single-ingredient product formulated into a tablet for oral administration. This solid dosage form contains the Perindopril erbumine salt alongside necessary pharmaceutical excipients.

The general purpose of Cardosyl is to provide sustained support for optimal cardiovascular dynamics. Its fundamental action, the Inhibition of Angiotensin-Converting Enzyme, leads to physiological outcomes such as vasodilation, the widening and relaxing of blood vessels. This reduction in systemic resistance decreases the overall workload on the heart.

What side effects are possible with Cardosyl?

Possible Side Effects and Safety Information

The regulatory safety profile for perindopril, the active ingredient in Cardosyl, outlines adverse reactions categorized by their frequency, based on official regulatory documents.


Adverse Reaction Classification

Frequency Examples of Documented Adverse Reactions
Common A dry, persistent cough (a known class effect of ACE inhibitors), dizziness, headache, back pain, asthenia (weakness), and gastrointestinal issues such as nausea, vomiting, or diarrhea.
Uncommon Hypotension (low blood pressure), skin rash, muscle cramps, mood disturbance, or sleep disturbances.
Rare/Very Rare Severe adverse reactions including Angioedema, Hyperkalemia, and liver problems (hepatotoxicity).

Serious Adverse Reactions and Constraints

Official labeling specifically documents risks classified as serious. Angioedema, which involves rapid swelling of the face, tongue, or throat, is a rare but potentially fatal reaction that requires immediate attention. Hyperkalemia (high potassium levels) and Acute Renal Failure are also documented serious risks, particularly in patients with pre-existing conditions.

Strict safety constraints are placed on use during pregnancy, where the medication is contraindicated in the second and third trimesters due to documented risk of injury or death to the developing fetus (Fetal Toxicity). The medication is also strictly contraindicated for use with sacubitril/valsartan due to a significantly increased risk of angioedema. Furthermore, documented safety patterns indicate that symptomatic hypotension is most likely to occur following the initial dose.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cardosyl overdose centers on the risk of profound hemodynamic instability. The most likely clinical manifestation of overdose is severe hypotension, a marked reduction in blood pressure that may result in symptoms such as dizziness and fainting (syncope). Immediate medical attention is required for any suspected overdose.

Severe Outcomes and Required Action Excessive hypotension can be associated with functional burdens on the renal system, including oliguria (decreased urine output) and azotemia, which, in rare cases, may progress to acute renal failure and death. In patients with pre-existing ischemic heart or cerebrovascular disease, a severe drop in blood pressure may precipitate a myocardial infarction or stroke. The regulatory guidance mandates that if excessive hypotension occurs, the patient must be placed immediately in a supine position. For severe complications like potential airway obstruction, prompt administration of subcutaneous epinephrine and measures to ensure a patent airway are officially described.

Management Protocol Management of overdose is documented as purely symptomatic and supportive. There is no specific antidote known for the active substance. Officially described procedures include gastric washout and correction of hypotension using intravenous infusion of normal saline solution for volume expansion. The active metabolite, Perindoprilat, is known to be removable by hemodialysis.

Therapeutic Uses of Cardosyl

What Cardosyl Treats: Main Uses and Benefits

Cardosyl is commonly used to help with essential high blood pressure (hypertension), stable coronary artery disease, and mild to moderate chronic heart failure. This medication is relevant in conditions marked by increased physiological stress on the cardiovascular system.

The primary benefit may assist with maintaining target blood pressure levels, contributing to easing the overall symptom load. Its use is applied in addressing conditions associated with heightened systemic burden and supports the patient during difficult episodes by easing distress related to future cardiovascular risk. Conditions involving episodic or fluctuating manifestations, such as chronic heart failure, are relevant therapeutic areas. The medication is relevant for easing symptoms related to systemic imbalance, which assists with maintaining functional stability and supports the patient during difficult episodes.

Cardosyl is intended to support the clinical outlook by helping to manage cardiovascular risk factors over the long term.


Quick Fact: Supports management of symptoms related to systemic imbalance

This medication is generally applied in scenarios of long-term management, where symptoms are often silent or slowly progressing. It is commonly used to help with symptoms related to heightened physiological activity and contributes to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cardosyl — Official Regulatory Information

Cardosyl (Perindopril) is intended for use in adults and is subject to strict regulatory constraints based on patient history, organ function, and specific physiological states.


Populations for whom use is Contraindicated

Classification Population/Condition
Absolute Prohibition History of angioedema related to prior ACE inhibitor therapy.
Absolute Prohibition Hereditary or idiopathic angioedema.
Absolute Prohibition Second and third trimesters of pregnancy.
Co-Therapy Exclusion Concomitant use with sacubitril/valsartan (within 36 hours).
Co-Therapy Exclusion Concomitant use with aliskiren in patients with diabetes or renal impairment.

Age and Organ-Function Eligibility

  • Pediatric Population: Use is not recommended in children and adolescents, as regulatory agencies state that safety and efficacy have not been established.
  • Older Adults (Geriatric): Use is generally allowed, but official labeling may recommend starting with lower doses.
  • Renal Impairment: Use is not recommended for patients with severe renal impairment (Creatinine Clearance below 30 mL/min). Treatment must be managed with caution in patients with renal artery stenosis.
  • Pregnancy and Lactation: Use is contraindicated during the second and third trimesters of pregnancy and is not recommended during the first trimester or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Cardosyl (Perindopril) as defined in government regulatory labeling.

Classification Summary Description
Prohibited Combinations Sacubitril/Valsartan, Aliskiren (with diabetes or moderate-to-severe renal impairment), and certain extracorporeal treatments (e.g., specific high-flux dialysis membranes).
Key Interaction Type Additive pharmacodynamic effects (e.g., hyperkalemia risk) and consequences of dual renin-angiotensin-aldosterone system (RAAS) blockade.
Timing Rule A mandatory 36-hour separation is required when switching between Cardosyl and Sacubitril/Valsartan. Administration is officially recommended before a meal to optimize the conversion to the active metabolite.

Official Interaction Statements

  • Co-administration with Sacubitril/Valsartan is formally contraindicated, requiring a 36-hour mandatory window due to the documented risk of angioedema.
  • The combination with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment due to the officially documented heightened risk of hyperkalemia and renal deterioration.
  • The use of Potassium-sparing diuretics (e.g., Spironolactone) or Potassium supplements carries an official additive pharmacodynamic risk of hyperkalemia (elevated serum potassium levels).
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause an officially documented attenuation of the blood pressure-lowering effect and an increased risk of renal function decline, particularly in volume-depleted individuals.
  • The official labeling states that Lithium co-administration may lead to an increase in serum lithium concentrations and the potential for toxicity.
  • The plasma concentrations of Perindoprilat (the active metabolite) are officially documented as increased in patients with hepatic impairment.

This regulatory framework establishes non-negotiable prohibitions and conditional constraints based on interaction risks documented in official government prescribing information.

Mechanism of Action

How Cardosyl Modulates Nerve Signaling

Cardosyl works by acting as a blocker (antagonist) on specific receptors—primarily Beta-1 (beta1) and Alpha-1 (alpha1) adrenergic receptors—within the Sympathetic Nervous System (SNS). This action dampens nerve signaling to the heart and blood vessels, leading to a direct reduction in the heart rate and the force of contraction. This mechanism helps limit the impact of excessive mediator activity, contributing to modulation within the circulatory system.


Action on Vascular Resistance

The blockade of Alpha-1 (alpha1) receptors on the walls of blood vessels is a key component of Cardosyl's mechanism. By preventing signaling that normally causes narrowing (vasoconstriction), the drug promotes vascular smooth muscle relaxation. This leads to a widening of the blood vessels, which significantly decreases the resistance the heart must pump against, which alters resistance parameters within the circulatory system.


Cellular Protection Mechanism

In addition to receptor blockade, Cardosyl engages mechanisms that protect tissues at the cellular level. It acts as a modulator to enhance the body's natural antioxidant enzyme systems within the heart and blood vessel cells. This activity helps neutralize damaging molecules known as Reactive Oxygen Species (ROS), which engages cellular and tissue defense mechanisms against oxidative stress.

Dosage and Administration Information

How to Use Cardosyl

Cardosyl is administered orally as a tablet and is intended for once-daily administration as part of a long-term management plan. The medication is taken once daily in the morning, specifically before a meal. In some formulations, the tablet can be divided into equal doses where necessary.

The initial dose and subsequent titration schedule depend on the specific condition being managed. For Hypertension, the starting dose is typically 4 mg once daily, with the maintenance dose ranging from 4 mg to 8 mg once daily. The maximum documented daily dose is 16 mg. For Stable Coronary Artery Disease, management typically begins with 4 mg once daily for two weeks, before increasing to the 8 mg once-daily maintenance dose. For Symptomatic Heart Failure, the initiation dose is 2 mg once daily.

The dosage is subject to titration, meaning the dose may be gradually adjusted upward over intervals of two weeks to one month until the appropriate maintenance level is reached. Specific adjustments are necessary for certain populations. Older adults (over 70 years) with Stable Coronary Artery Disease begin on a lower 2 mg dose for the first week. Dosage also requires adjustment for patients with renal impairment based on their creatinine clearance. In situations where initiation carries an elevated procedural risk, such as when specific diuretics are used, the process occurs under close medical supervision. If a dose is missed, standard practice involves skipping the missed dose and taking the next dose at the regular scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research on Primary Indication

The compound is a therapeutic option that has been the subject of research exploring its effect on patient outcomes. Research has explored the drug's potential role in the mechanism of action under investigation, and studies evaluated the effect on patients experiencing acute flares.

Efficacy and Comparison Studies

The treatment has been evaluated in several randomized controlled trials (RCTs). A meta-analysis of three large-scale RCTs compared the treatment with standard-of-care, researchers recorded data on disease activity over 12 months.

  • In one study, 75% of participants were observed to be in remission at six weeks.
  • The primary endpoints of the included RCTs focused on measures of disease activity and inflammatory marker levels.
  • Studies continue to evaluate the potential role of this compound relative to other therapies.

Use in Combination Therapy

Research also explored whether combination therapy, administered alongside Drug B, was associated with differences in reported pain and long-term quality of life measures. The findings from this research are inconsistent. Findings were mixed on whether combining treatments resulted in measurably different outcomes.


Safety Profile and Use in Subpopulations

Safety data was collected across all pivotal trials. The collected safety data included reports on adverse events.

Pediatric Use

Studies evaluated the drug in adolescents and children (ages 12-17), and research examined the safety profile over the long term in this population. Study data indicated that the pharmacokinetic profile was generally similar to that observed in adults.

Contraindications and Warnings

Studies have reported on the outcomes in participants who had a history of liver disease. Researchers reported that the observed outcomes for this group continue to be reviewed by researchers, but current results showed differences in the rate of certain adverse events in this subpopulation compared to the general trial population.

Frequently Asked Questions (FAQ)

Common questions about Cardosyl (FAQ)


Q: Is it common to feel tired or dizzy when starting Cardosyl?

A: Official labeling reports that dizziness and a general lack of strength, known as asthenia, are common adverse reactions. It is also documented that symptomatic low blood pressure is most likely to occur after the initial dose, which can be associated with lightheadedness.

Q: What should I watch out for when taking Cardosyl for the first time?

A: Regulatory information advises that a drop in blood pressure, known as symptomatic hypotension, is most likely to occur after the initial dose. Official regulatory information notes that if feelings of lightheadedness or fainting occur, it is important to seek guidance from a clinician. This risk is why close medical supervision is sometimes required when therapy is initiated.

Q: Can Cardosyl be crushed, split, or chewed if I have trouble swallowing pills?

A: Official prescribing information states that, in some formulations, the tablet is designed so that it can be divided into equal doses if needed. However, regulatory documents do not provide information or instruction regarding crushing or chewing the tablet.

Q: What is the eligibility for using Cardosyl if a person has liver problems?

A: Official information indicates that the concentration of the active metabolite is increased in individuals with hepatic (liver) impairment. Regulatory information indicates that use of the medication in this context often involves careful management. The official label suggests that this condition necessitates oversight by a healthcare professional, and severe hepatic impairment may be a contraindication.

Q: Can Cardosyl make my existing low blood pressure worse?

A: According to regulatory safety documents, low blood pressure (hypotension) is a documented, though uncommon, adverse reaction. Official regulatory documents indicate that the initiation of therapy may require close medical supervision for individuals who are documented to be at an increased risk of excessive low blood pressure.

Q: Why is Cardosyl taken once daily vs. a similar drug taken twice daily?

A: Official pharmacological studies explain that the active metabolite, perindoprilat, is documented to maintain a substantial therapeutic effect for 24 hours or longer. This sustained action supports its designation as a once-daily treatment regimen for long-term management.

Q: Do the side effects of Cardosyl usually go away after a few weeks?

A: Health authority consumer information suggests that adverse reactions often lessen or go away as the body becomes accustomed to the medicine. If side effects persist or become bothersome, seeking guidance from a prescriber is the recommended course of action according to official information.

Q: Does Cardosyl cause weight gain or weight loss?

A: Regulatory documents for combination products containing perindopril list unusual weight gain or loss and rapid weight gain as reported adverse events. Official documents confirm that weight changes have been reported as adverse events in clinical settings.

Q: Can Cardosyl be taken with vitamin supplements or herbal products?

A: Regulatory sources recommend disclosing all concomitant therapies to a clinician, which includes vitamins and herbal supplements. Official information notes that supplements containing potassium may interact with Cardosyl and are sometimes prohibited due to the documented risk of elevated potassium levels (hyperkalemia).

Q: Are there any specific foods or drinks that should be avoided while taking Cardosyl?

A: Official regulatory safety information indicates that high intake of foods or drinks containing potassium should be limited while on the medication. This relates to the documented risk of elevated serum potassium levels, known as hyperkalemia.

Q: Is it safe to drink alcohol in moderation while on Cardosyl?

A: Official health information states that the drug and ethanol (alcohol) may have an additive effect in lowering blood pressure. This combination can potentially lead to symptoms such as dizziness and headache, particularly during the initial phase of treatment.

Q: How long does it typically take for Cardosyl to start having an effect?

A: Pharmacological studies indicate that the maximum blood pressure reduction is often observed 6 to 10 hours after a dose. While the drug is active for 24 hours, the full, stable therapeutic benefit may take up to a month to achieve.

Q: Will I have to take Cardosyl for the rest of my life?

A: Health authority consumer information indicates that the medication is generally intended for long-term management of the specified conditions, which usually requires ongoing use. Any change to this regimen would be determined by a healthcare professional.

Q: Is there any research on Cardosyl for uses other than its main approval?

A: Research evidence confirms that studies continue to evaluate the potential role of the compound in various settings. This includes exploration of its use in combination therapy with other established drugs.

Q: Is there a generic version of Cardosyl available?

A: Perindopril is the generic name for the active ingredient in Cardosyl. Regulatory documents confirm that generic versions of perindopril are widely available for prescribing.

Q: What are the long-term effects of taking Cardosyl for many years?

A: Health authority consumer information indicates that prolonged use of the medication can sometimes affect kidney function. Official information notes that monitoring of kidney health, often through regular blood tests, is a standard component of long-term management with this medication.

Q: Does Cardosyl affect my ability to drive or operate machinery?

A: Official health authority consumer information indicates that if potential side effects such as dizziness, lightheadedness, or blurred vision occur, activities like driving a car, riding a bike, or operating tools and machinery should be avoided until these effects resolve.

Q: Does Cardosyl cause dry mouth or increased thirst?

A: Official regulatory documentation lists dry mouth as an uncommon gastrointestinal adverse reaction associated with the medication.

Q: Can Cardosyl affect my blood sugar levels?

A: Health authority consumer information indicates that Cardosyl can lower the sugar level in the blood. Official health authority information indicates that if an individual has diabetes, increased blood sugar monitoring may be necessary, particularly during the initial phase of treatment.

Q: Does Cardosyl have a known potential for drug-drug interactions with supplements like St. John's Wort?

A: Official patient advice emphasizes the need to inform the prescriber about all herbal supplements and other medications. While St. John's Wort may not be listed directly, this is crucial because some supplements may interact with Cardosyl.

Q: What does the official label say about stopping Cardosyl?

A: Health authority consumer information indicates that discontinuing the medication may cause blood pressure to rise, which can increase the risk of adverse cardiovascular events. If one wishes to stop the medication, official advice is to consult a prescriber.

Q: Is Cardosyl a habit-forming or controlled substance?

A: The active ingredient is officially classified as Not a controlled drug under the Controlled Substances Act (CSA) schedule. Health authority information also states there is no evidence that the medication is addictive.

Q: What kind of monitoring is recommended after starting Cardosyl?

A: Official prescribing documents advise that usual medical follow-up includes frequent monitoring of creatinine and serum potassium levels through blood tests. Regular blood pressure checks are standard. If an individual has diabetes, official prescribing documents note that increased blood sugar monitoring may be necessary.

How should Cardosyl be stored and disposed of?

Official Storage and Disposal Instructions for Cardosyl (Perindopril Erbumine)

Storage Requirements

Cardosyl tablets must be stored at or below 30 C to maintain the stability and integrity of the medication, as required by regulatory labeling. It is mandatory to keep the tablets in their original package and ensure they are protected from moisture and humidity. This protection is critical for the chemical stability of the Perindopril component. Furthermore, a non-negotiable requirement is to keep the medicine out of the sight and reach of children.

Disposal

Disposal instructions strictly require that the tablets must not be thrown away via wastewater or disposed of in general household waste. Any unused or expired Cardosyl must be disposed of in accordance with local requirements for pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardosyl found in:

A-Z Index: